BBIBP-CorV is being developed by the Beijing Institute of Biological Products affiliated to state-owned China National Pharmaceutical Group, known as Sinopharm.Current Status: BBIBP-CorV is under a phase I/II trial in China.Mode of Action: BBIBP-CorV contains an inactivated version of SARS-CoV-2 and the adjuvant aluminum hydroxide. After vaccination, the immune system is induced to produce neutralizing antibodies against the novel coronavirus, thus building up immunity.